ASCL3: A Potential Drug Target and Biomarker (G56676)

Target Name: ASCL3

NCBI ID: G56676

ASCL3

ASCL3: A Potential Drug Target and Biomarker

ASCL3 (Achaete-scute homolog 3) is a gene that has been identified in various organisms, including bacteria, archaea, and eukaryotes. ASCL3 is a member of the Achaete family, which is known for its role in the regulation of cell growth, differentiation, and stress tolerance. The discovery of ASCL3 and its potential functions as a drug target and biomarker make it an attractive target for researchers to investigate.

Drug Target Potential

ASCL3 has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress response. Several studies have demonstrated that ASCL3 functions as a negative regulator of the TGF-β signaling pathway, which is known to play a major role in cell proliferation, differentiation, and survival.

The TGF-β pathway is a well-established target for many diseases, including cancer, neurodegenerative diseases, and developmental disorders. Activation of the TGF-β pathway has been implicated in the development and progression of various diseases, including cancer, neurofibromatosis, and Alzheimer's disease.

ASCL3 has been shown to regulate the activity of the TGF-β pathway by inhibiting the activity of the transcription factor, SMAD. This inhibition of SMAD activity at the level of the gene has led to the accumulation of TGF-β signaling pathway-active intracellular stress factors, such as reactive oxygen species (ROS), which can cause cellular damage and contribute to the development of various diseases.

Biomarker Potential

ASCL3 has also been shown to serve as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The expression of ASCL3 has been observed in various tissues and organs, including the brain, spinal cord, heart, and kidneys, which suggests that it may play a role in the development and progression of these diseases.

ASCL3 has also been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This downregulation of ASCL3 has been associated with the development of cancer stem cells, which are capable of self-replication and the formation of new cancerous tumors.

In addition, ASCL3 has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The downregulation of ASCL3 has been observed in the brains of individuals with these conditions, which suggests that it may play a role in the development and progression of these diseases.

Conclusion

In conclusion, ASCL3 is a gene that has been identified in various organisms and has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress response. The discovery of ASCL3 has made it an attractive target for researchers to investigate, and its potential as a drug target and biomarker make it a promising target for the development of new therapies for various diseases. Further research is needed to fully understand the functions of ASCL3 and its potential as a drug target and biomarker.

Protein Name: Achaete-scute Family BHLH Transcription Factor 3

Functions: Transcriptional repressor. Inhibits myogenesis (By similarity)

The "ASCL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASCL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets